Navigation Links
completion in Medical Technology

Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy

NEWPORT BEACH, Calif., July 28 /PRNewswire/ -- Hoag Memorial Hospital Presbyterian today announced promising data from a clinical study showing patient-specific cancer vaccines derived from patients' own cancer cells and immune cells were well tolerated and resulted in impressive lo...

Relievant Medsystems Announces Completion of $20 Million Financing

REDWOOD CITY, Calif., July 7 /PRNewswire/ -- Relievant Medsystems, Inc., developer of a novel, minimally invasive treatment for chronic low back pain, reported today that it has completed a $20 million private equity financing. The financing was led by Morgenthaler Ventures with existing investor...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

SEATTLE, June 22 /PRNewswire-FirstCall/ -- Updated follow-up phase III EXTEND (PIX 301) clinical trial data enhances previously reported superior response rates for pixantrone over comparator including in high risk patient subgroups Additional Clinical Studies Also Highlighted at Pan ...

TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin

SAN DIEGO, May 14 /PRNewswire/ -- TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009. (Logo: http://www.newscom....

Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers

SAN DIEGO, May 6 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM ) and its subsidiary Tissue Repair Company (TRC) today announced the completion of recruitment for the pioneering Phase 2b MATRIX clinical trial to evaluate the safety and efficacy of the Excellarate(TM) product cand...

Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes

First study evaluating DUROS(R) continuous delivery of exenatide for the treatment of type 2 diabetes HAYWARD, Calif., April 24 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the completion of patient accrual to a phase 1b clinical study evaluating ITCA 650 (DUROS(R) continuous d...

PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)

- Company Reports Significant Uptake of PlasmaBlade by U.S. Surgeons Since Product Launch - PALO ALTO, Calif., April 7 /PRNewswire/ -- PEAK Surgical, Inc., a medical device company that has developed a new tissue dissection system based on a proprietary technology, announced today several mil...

InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study

LOS ALTOS, Calif., March 11 /PRNewswire/ -- InteKrin Therapeutics, Inc., a clinical stage biopharmaceutical company focused on diabetes, metabolism and obesity, today announced it has completed enrollment of a 360 patient Phase 2b study of INT131, a novel, non-TZD selective modulator of PPAR gamma...

Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)

Study Evaluating Cysteamine in Collaboration with UC San Diego NOVATO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced the completion of patient enrollment in its Phase 2a open-label clinical trial t...

Phidea Srl and Marvin Research Srl Announce Completion of Merger

MILAN, Italy, January 22 /PRNewswire/ -- Phidea S.r.l. a full service and leading clinical research organization (CRO), today announced that it has completed the merger with Marvin Research S.r.l., a CRO focused on Phase I to Phase IV clinical trials. (Logo: http://www.newscom.com/cgi-...

MannKind Reports Successful Completion of Device Bioequivalence Trial

VALENCIA, Calif., Jan. 13 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD ) today announced successful completion of its trial to demonstrate equivalence of its commercial inhaler to the version of the device that was used in clinical trials to deliver AFRESA(TM), MannKind's ultra...

Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483

SUNNYVALE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced that the company has completed a Phase 1 clinical trial with PCI-27483, the company's novel, first-in-class small-molecule Factor VIIa inhibitor. The trial was conducted in sixteen (16) healt...

Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study

HOPKINTON, Mass., Oct. 13 /PRNewswire/ -- Facet Solutions, Inc. today announced the completion of 6 month follow-up on 20 patients from its US IDE Pilot Study. The results show a 78% reduction in Oswestry Disability Index (ODI) scores, and an 80% reduction in Visual Analog Scores (VAS) for sym...

SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen

Top Line Clinical Results Expected in November 2008 BOTHELL, Wash., Oct. 9 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (Amex: DDD ) announced today the completion of patient enrollment and dosing for the third of its three pivotal trials to evaluate the safety and efficacy of its formulati...

Evalve Announces Enrollment Completion of the EVEREST Randomized Study

EVEREST Becomes First Trial of its Kind to Achieve Enrollment Milestone MENLO PARK, Calif., Sept. 30 /PRNewswire/ -- Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today the completion of randomized enrollment in the Endovascular...

Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients

- 100 mg cohort demonstrates potent antiviral activity and favorable safety profile - CAMBRIDGE, Mass., Sept. 4 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged in the discovery and development of drugs for...

Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000

9,395 Women Enrolled in Trial Sponsored by Medical Research Council LEXINGTON, Mass., Aug. 22 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV ) announced today the completion of enrollment in Protocol MDP 301, a Phase III clinical trial of PRO 2000, the Company's candi...

Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845

SHELTON, Conn., Aug. 5 /PRNewswire/-- Cara Therapeutics, Inc. today announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of acute and chronic pain. The drug candidate was safe and well-t...

Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease

Agency Supports Amigal Move to Phase 3; Eligible for Accelerated Approval; Final Global Regulatory Plan Expected by Year End CRANBURY, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD ), a biopharmaceutical company developing small molecule, orally-administere...

Novare Announces Completion of First Pediatric Single Port Spleen Removal Using RealHand(R) HD Instruments

8-year-old patient receives 'hidden scar' procedure; Pediatrics becomes 4th surgical specialty to benefit from single port surgery with RealHand HD instruments CUPERTINO, Calif., July 28 /PRNewswire/ -- Novare Surgical Systems announced the successful completion of...

Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program

DANBURY, Conn., July 16 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that its two pivotal Phase III VIAject(TM) clinical trials are now complete, with the last study patient visit on July 14, 2008. Results of the full trial will be released either at Biodel's poster pre...

Sosei Announces Completion of Phase III Trial for NorLevo(R)

TOKYO, July 10 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced the completion of a Japanese Phase III clinical trial for the emergency contraceptive pill (ECP) SOH-075 (NorLevo(R)). Sosei acquired the exclusiv...

XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain

VALLEY COTTAGE, N.Y., June 30 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB ; TASE: XTL) today announced that it has completed patient randomization into its Phase 2b study of Bicifadine -- a serotonin and norepinephrine reuptake inhibitor (SNRI) -- for the treatment of ...

ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients

- Phase 3 Study in 681 Stem Cell Transplant Patients Represents First Pivotal Study on a New Antiviral CMV Therapy in Stem Cell Transplant in Over a Decade - - Company Also Provides Timing of Phase 3 Data Disclosure and Regulatory Submi...

N30 Pharma Announces Completion of Phase 1 Clinical Studies With N30-201

BOULDER, Colo., May 5 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that target endogenous s-nitrosothiols, announced today that it has successfully completed Phase I study of N30-201 in patients with mild to...

Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein

EDISON, N.J., April 21 /PRNewswire/ -- Nostrum, a privately-held company based in Edison, New Jersey, announced today that it has successfully completed its early, primate, proof-of-concept study for its novel thrombolytic clot-buster protein currently known as SMRX11. Nostrum's Symmetrix subs...

Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)

- Full Results to be Presented at European Association for the Study of the Liver Annual Meeting - SAN FRANCISCO, April 10 /PRNewswire/ -- Antipodean Pharmaceuticals, Inc. announced today that it has completed its Phase 2 study of its lead compound, MitoQ(R) (mitoquinone)...

On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments

ANN ARBOR, Mich., Feb. 19 /PRNewswire/ -- Compendia Bioscience, Inc. today announced results of a second productive year, including a renewed and expanding commitment from all major customers and the addition of several "Top 20" oncology drug companies to its customer roster. The new customers...

Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas

SOUTH SAN FRANCISCO, Calif., Feb. 13 /PRNewswire/ -- Raven biotechnologies, inc., a privately held company focused on the development of monoclonal antibody therapeutics (MAbs) for cancer, today announced that it completed enrollment of patients in the maximum tolerated dose (MTD) cohort expan...

CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)

- Tyrima Exhibits Excellent Safety Profile and Favorable Pharmacokinetics in Phase I Studies - RESEARCH TRIANGLE PARK, N.C., Jan. 16 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the...

Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus

CAMBRIDGE, Mass., Jan. 15 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced today the successful completion of a Phase Ib clinical study of TRX1, a novel humanized anti-...

Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement

EAST SETAUKET, N.Y., Dec. 18 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) a developer of improved methods for both detection and treatment of cancer, announced the closing of a private placement. In the placement, Lixte sold 1,000,000 shares of its Co...

NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study

MAPLE GROVE, Minn., Dec. 7 /PRNewswire/ -- NeuroVasx, Inc. announced today the completion of a private placement of common stock in the amount of $8,500,000 with MJSK of Minneapolis, MN and the Stephens Group of Little Rock, AR. Terms of the financing were not disclosed. The company also ann...

ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer

SAN DIEGO, Dec. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that it has completed pa...

Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy

Milestone Triggers Payment to Sangamo from JDRF RICHMOND, Calif., Dec. 4 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced today that the company has completed enrollment of its randomized, double-blind, repeat-dosing, placebo-controlled, multi-center P...

Aida Announces Completion of Anti-Cancer Drug Phase Two Testing

SANTA MONICA, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that the Company has successfully completed Phase II field testing of its anti-cancer drug, Rh-Apo2L. The product of over a decade of research, Rh-Apo2L is intended to ...

Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months

Data Presented Today at the American Heart Association Scientific Sessions 2007 in Orlando, Florida BOCA RATON, Fla., Nov. 7 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI ) today announced the successful completion of its Phase 2b trial of NicVAX(R) (Ni...

ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study

SAN DIEGO, Oct. 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that it has completed p...

EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407

Follow up Combination Therapy Trial planned for 2008 TARRYTOWN, N.Y., Oct. 8 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that it has completed its Phase I clinical trial for EPC2407. The trial has met all of its objectives. EPC...

Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease

SAN MATEO, Calif., Oct. 3 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing anti-inflammatory therapeutics for chronic and acute inflammatory diseases, announced today the completion of enrollment and patient dosing in its Phase II clinical st...
Other Tags
(Date:9/23/2014)... their own "antifreeze" proteins to survive in the ... effect, researchers funded by the National Science Foundation ... inside their bodies resist melting even when temperatures ... be an undesirable consequence of the evolution of ... of Oregon doctoral student Paul Cziko, who led ...
(Date:9/23/2014)... multidisciplinary team at the University of Wisconsin-Madison and the ... affordable way to screen for neural toxins, helping flag ... Institutes of Health (NIH) announced today that the UW-Madison ... to continue the promising work as part of the ... receive approximately $7 million over the three-year project. ...
(Date:9/23/2014)... (PHILADELPHIA) Researchers have encountered variants or isoforms in ... accidental byproducts. A recent study, published in the journal ... called isomiRs have abundances that depend on geographic subpopulations ... a given miRNA may not be the one typically ... that microRNA isoforms are much more common than we ...
Breaking Biology News(10 mins):Antifreeze proteins in Antarctic fish prevent both freezing and melting 2Antifreeze proteins in Antarctic fish prevent both freezing and melting 3UW-Madison team developing 'tissue chip' to screen neurological toxins 2UW-Madison team developing 'tissue chip' to screen neurological toxins 3Slight alterations in microRNA sequences hold more information than previously thought 2Slight alterations in microRNA sequences hold more information than previously thought 3
(Date:9/23/2014)... (September 23, 2014) Both patients and healthcare ... computed tomography (CT) colonography greatly outweighs the potential ... precipitated by false-positive diagnoses, according to a new ... journal Radiology . , Diagnostic tests used ... organ. However, when screening for colorectal cancer with ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Trevera ... services market. Included are Oracle Managed Services ... Trevera supports all versions of Oracle E-Business Databases ... releases. , Trevera has announced a significant ... that need help with their software technology management, ...
(Date:9/23/2014)... September 23, 2014 The Sloane ... in Singapore and Malaysia providing advanced aesthetic dermatology ... powder to its impressive skin care repertoire. Specially ... skin’s defences against the evil forces of aging, ... glow simultaneously, this new addition is revolutionizing the ...
(Date:9/23/2014)... NC (PRWEB) September 23, 2014 ... a national research university located In the Piedmont ... joined UNCG as co-director of the Center for ... bioanalytical chemistry, comes to UNCG after nearly a ... Northwest National Laboratory, Biological Sciences Division. , ...
(Date:9/23/2014)... HealthDay Reporter MONDAY, ... marches demanding action on climate change, a new study ... the United States may soon exacerbate many existing health ... illnesses are expected to increase as the number of ... Patz, director of the Global Health Institute at the ...
Breaking Medicine News(10 mins):Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3Health News:Trevera, Inc adds Management Support to Services 2Health News:Trevera, Inc adds Management Support to Services 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 3
Other Contents